The headlines point to three big pharma moves in Asia:
AstraZeneca is making a reported $2 billion play around ivonescimab, Novo Nordisk has licensed Hengrui’s experimental oral metabolic drug, and Merck is expanding its KRAS portfolio. Details on the AstraZeneca and Merck items aren’t available in the sources retrieved here, so their terms and rationale should be treated as unverified.
Novo–Hengrui:
Novo agreed to pay $300 million upfront for rights outside mainland China, Hong Kong, Macao and Taiwan to HRS-1596, a Phase 1-ready GLP-1/GIP dual agonist with potential for once-weekly oral dosing. Development, regulatory and commercial milestones could take the deal to $2.6 billion, plus royalties. The drug is still early-stage, not an established treatment.
The broader theme is global drugmakers licensing Chinese-developed candidates to strengthen pipelines in competitive areas—metabolic disease, oncology antibodies and targeted cancer drugs.
Sources:
Novo to pay up to $2.6 billion to China's Hengrui for rights ...
Novo and Hengrui strike $2.6bn obesity drug deal
Novo Nordisk Acquires Hengrui's GLP-1 Pill for ...
Novo Nordisk Licenses Experimental Once-Weekly Obesity ...
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug ...
Novo Nordisk Licenses Experimental GLP-1 Pill from Hengrui
Novo Nordisk strikes $2.6B obesity drug deal with China's Hengrui
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Hengrui Pharma shares rise as Novo Nordisk signs $2.6 ...
Novo to pay Hengrui up to $2.6B for a once-weekly obesity ...
China's Hengrui licenses weight-loss drug to Denmark's ...